Abstract
It has now become common sense to say that treatment paradigms in oncology are changing. From large range, toxic, deleterious treatments that had only a very small margin of benefit we are now going to targeted, more specific, more effective therapies. This change challenges research mechanisms, treatment habits and health economics. Even if cancer is a widespread disease and a major cause of chronic illness and mortality, costs of large-scale research and development of a competitive business model begin hampering innovation.